Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling

Таргетная терапия распространённой карциномы околощитовидных желёз на основе геномного и транскриптомного профилирования
Martin Faßnacht, Hanno Glimm, Daniel Hübschmann, Maria‐Veronica Teleanu, Stefan Fröhling, Albrecht Stenzinger, Matthias Kroiß, Andreas Möck, Nagarajan Paramasivam, Arne Jahn, Nicolas Schlegel, Stefan Kircher, Carmina Teresa Fuß, Sebastian Pirmann, Christoph Terkamp, Laura‐Sophie Landwehr, Christina Lenschow
2023-02-19

RNA sequencingimmune checkpoint inhibitionparathyroid carcinomatargeted therapywhole-genome sequencing
Parathyroid carcinoma (PC) is an ultra-rare malignancy with a high risk of recurrence after surgery. Tumour-directed systemic treatments for PC are not established. We used whole-genome and RNA sequencing in four patients with advanced PC to identify molecular alterations that could guide clinical management. In two cases, the genomic and transcriptomic profiles provided targets for experimental therapies that resulted in biochemical response and prolonged disease stabilization: (a) immune checkpoint inhibition with pembrolizumab based on high tumour mutational burden and a single-base substitution signature associated with APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) overactivation; (b) multi-receptor tyrosine kinase inhibition with lenvatinib due to overexpression of FGFR1 (Fibroblast Growth Factor Receptor 1) and RET (Ret Proto-Oncogene) and, (c) later in the course of the disease, PARP (Poly(ADP-Ribose) Polymerase) inhibition with olaparib prompted by signs of defective homologous recombination DNA repair. In addition, our data provided new insights into the molecular landscape of PC with respect to the genome-wide footprints of specific mutational processes and pathogenic germline alterations. These data underscore the potential of comprehensive molecular analyses to improve care for patients with ultra-rare cancers based on insight into disease biology.
1
Comprehensive profiling revealed genome-wide signatures of mutational processes and pathogenic germline alterations, supporting molecularly guided care in ultra-rare cancers.
2
FGFR1 and RET overexpression supported lenvatinib treatment, while homologous recombination repair defects later prompted olaparib therapy.
3
High tumour mutational burden and an APOBEC-associated mutational signature supported pembrolizumab treatment, which achieved clinical benefit.
4
In two cases, genomically informed experimental therapies produced biochemical responses and prolonged disease stabilization.
5
Whole-genome and RNA sequencing of four patients with advanced parathyroid carcinoma identified molecular alterations potentially guiding individualized systemic treatment.

Advanced parathyroid carcinoma in patients with recurrent or unresectable disease

Genomic and transcriptomic alterations guiding targeted systemic therapy and their association with biochemical response and prolonged disease stabilization

Publication Details
Publication Date
2023-02-19
Journal
Publisher
ISSN
Cited by
23
Access Type
Author Information
Authors
Martin Faßnacht
Hanno Glimm
Daniel Hübschmann
Maria‐Veronica Teleanu
Stefan Fröhling
Albrecht Stenzinger
Matthias Kroiß
Andreas Möck
Nagarajan Paramasivam
Arne Jahn
Nicolas Schlegel
Stefan Kircher
Carmina Teresa Fuß
Sebastian Pirmann
Christoph Terkamp
Laura‐Sophie Landwehr
Christina Lenschow
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%